Author ORCID Identifier
Thrombotic microangiopathies (TMAs) as a disease group represent a diagnostic and clinical challenge to practitioners. Presentations, which at times have overlapping symptomatology or have undetermined etiologies, emphasize the need for a constant reassessment of what is known about this disease group in order to determine not only how to best treat patients but also to develop targeted approaches to test for a given etiology. Likewise, in those instances when excluding diagnoses is the only available option, timely adjustment of therapy due to lack of therapeutic response needs to be achieved in the most efficient way. It is with this in mind that this topic-specific collection of articles was conceptualized to provide a forum to review not only what is currently known about these disease entities but also to present new findings in order to keep readers abreast of ways in which these diseases can be discerned. This is important since each of these etiologies responds to different therapies with a distinct road to recovery.
atypical hemolytic uremic syndrome, diagnosis, drug-induced, microangiopathic hemolytic anemia, therapy, thrombotic microangiopathy, thrombotic thrombocytopenic purpura
Frontiers in Medicine
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Maitta RW, Raval JS, Reeves HM and Fontaine MJ (2021) Editorial: Thrombotic Microangiopathies, Diagnostic and Therapeutic Advances. Front. Med. 8:778352. doi: 10.3389/fmed.2021.778352